https://wiki.unissula.ac.id/index.php?action=history&feed=atom&title=Linagliptin
Linagliptin - Riwayat revisi
2026-09-16T08:45:57Z
Riwayat revisi halaman ini di wiki
MediaWiki 1.46.0
https://wiki.unissula.ac.id/index.php?title=Linagliptin&diff=27506&oldid=prev
Maintenance script: Presentation V4: sitasi, referensi, Math, Wikimedia Commons, dan atribusi
2026-08-29T18:08:25Z
<p>Presentation V4: sitasi, referensi, Math, Wikimedia Commons, dan atribusi</p>
<table style="background-color: #fff; color: #202122;" data-mw-interface="">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="id">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Revisi sebelumnya</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revisi per 29 Agustus 2026 18.08</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Baris 1:</td>
<td colspan="2" class="diff-lineno">Baris 1:</td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">'''Linagliptin''' adalah obat yang digunakan untuk mengobati </del>[[<del style="font-weight: bold; text-decoration: none;">diabetes melitus tipe 2]] bersamaan dengan olahraga dan diet</del>. Linagliptin <del style="font-weight: bold; text-decoration: none;">termasuk dalam kelas obat yang disebut "[[penghambat dipeptidil peptidase-4</del>]]<del style="font-weight: bold; text-decoration: none;">". Obat ini secara umum kurang disukai dibandingkan [[metformin]] dan [[sulfonilurea]] sebagai pengobatan awal. Obat ini digunakan dengan cara diminum.</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>[[<ins style="font-weight: bold; text-decoration: none;">File:Linagliptin</ins>.<ins style="font-weight: bold; text-decoration: none;">svg|thumb|right|280px|</ins>Linagliptin]]</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>[[<del style="font-weight: bold; text-decoration: none;">Efek samping</del>]] <del style="font-weight: bold; text-decoration: none;">yang umum termasuk radang hidung </del>dan <del style="font-weight: bold; text-decoration: none;">tenggorokan</del>. <del style="font-weight: bold; text-decoration: none;">Efek samping yang serius mungkin termasuk </del>[[<del style="font-weight: bold; text-decoration: none;">edema angioneurotik|angioedema</del>]<del style="font-weight: bold; text-decoration: none;">], </del>[[<del style="font-weight: bold; text-decoration: none;">pankreatitis</del>]], <del style="font-weight: bold; text-decoration: none;">nyeri sendi</del>. <del style="font-weight: bold; text-decoration: none;">Penggunaan pada </del>[[<del style="font-weight: bold; text-decoration: none;">kehamilan</del>]] dan [[<del style="font-weight: bold; text-decoration: none;">menyusui</del>]] <del style="font-weight: bold; text-decoration: none;">tidak dianjurkan</del>. Linagliptin <del style="font-weight: bold; text-decoration: none;">adalah penghambat dipeptidil peptidase</del>-<del style="font-weight: bold; text-decoration: none;">4 yang bekerja </del>dengan <del style="font-weight: bold; text-decoration: none;">meningkatkan produksi </del>[<del style="font-weight: bold; text-decoration: none;">[insulin</del>]<del style="font-weight: bold; text-decoration: none;">] dan menurunkan produksi [[glukagon]] oleh pankreas</del>.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">'''Linagliptin''' adalah obat yang digunakan untuk mengobati </ins>[[<ins style="font-weight: bold; text-decoration: none;">diabetes melitus tipe 2</ins>]] <ins style="font-weight: bold; text-decoration: none;">bersamaan dengan olahraga </ins>dan <ins style="font-weight: bold; text-decoration: none;">diet</ins>.<ins style="font-weight: bold; text-decoration: none;"><ref></ins>[<ins style="font-weight: bold; text-decoration: none;">https://www.drugs.com/monograph/linagliptin.html Linagliptin Monograph for Professionals]. ''Drugs.com''. American Society of Health-System Pharmacists.</ref><ref></ins>[<ins style="font-weight: bold; text-decoration: none;">https://archive.org/details/sim_annals-of-pharmacotherapy_2012-03_46_3/page/358 Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus</ins>]<ins style="font-weight: bold; text-decoration: none;">. ''The Annals of Pharmacotherapy''. March 2012. Vol. 46 (3). hlm. 358–67. doi:10.1345/aph.1Q522.</ref> Linagliptin termasuk dalam kelas obat yang disebut "</ins>[[<ins style="font-weight: bold; text-decoration: none;">penghambat dipeptidil peptidase-4</ins>]]<ins style="font-weight: bold; text-decoration: none;">".<ref>[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c797ea5c-cab7-494b-9044-27eba0cfe40f Tradjenta- linagliptin tablet</ins>, <ins style="font-weight: bold; text-decoration: none;">film coated]. ''DailyMed''. 21 April 2022</ins>.<ins style="font-weight: bold; text-decoration: none;"></ref> Obat ini secara umum kurang disukai dibandingkan </ins>[[<ins style="font-weight: bold; text-decoration: none;">metformin</ins>]] dan [[<ins style="font-weight: bold; text-decoration: none;">sulfonilurea</ins>]] <ins style="font-weight: bold; text-decoration: none;">sebagai pengobatan awal.<ref>[https://www.drugs.com/monograph/linagliptin</ins>.<ins style="font-weight: bold; text-decoration: none;">html </ins>Linagliptin <ins style="font-weight: bold; text-decoration: none;">Monograph for Professionals]. ''Drugs.com''. American Society of Health</ins>-<ins style="font-weight: bold; text-decoration: none;">System Pharmacists.</ref><ref>''British national formulary : BNF 76''. Pharmaceutical Press. 2018. hlm. 680. ISBN 9780857113382.</ref> Obat ini digunakan </ins>dengan <ins style="font-weight: bold; text-decoration: none;">cara diminum.<ref></ins>[<ins style="font-weight: bold; text-decoration: none;">https://www.drugs.com/monograph/linagliptin.html Linagliptin Monograph for Professionals</ins>]. <ins style="font-weight: bold; text-decoration: none;">''Drugs.com''. American Society of Health-System Pharmacists.</ref></ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Linagliptin telah disetujui untuk penggunaan medis di Amerika Serikat, Jepang, Uni Eropa, Kanada, dan Australia pada tahun 2011.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">[[Efek samping]] yang umum termasuk radang hidung dan tenggorokan. Efek samping yang serius mungkin termasuk [[edema angioneurotik|angioedema]], [[pankreatitis]], nyeri sendi.<ref>[https://www.drugs.com/monograph/linagliptin.html Linagliptin Monograph for Professionals]. ''Drugs.com''. American Society of Health-System Pharmacists.</ref><ref>''British national formulary : BNF 76''. Pharmaceutical Press. 2018. hlm. 680. ISBN 9780857113382.</ref> Penggunaan pada [[kehamilan]] dan [[menyusui]] tidak dianjurkan.<ref>''British national formulary : BNF 76''. Pharmaceutical Press. 2018. hlm. 680. ISBN 9780857113382.</ref> Linagliptin adalah penghambat dipeptidil peptidase-4 yang bekerja dengan meningkatkan produksi [[insulin]] dan menurunkan produksi [[glukagon]] oleh pankreas.<ref>[https://www.drugs.com/monograph/linagliptin.html Linagliptin Monograph for Professionals]. ''Drugs.com''. American Society of Health-System Pharmacists.</ref></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Linagliptin telah disetujui untuk penggunaan medis di Amerika Serikat,<ins style="font-weight: bold; text-decoration: none;"><ref>[https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000TOC.cfm Drug Approval Package: Tradjenta (linagliptin) Tablets NDA #201280]. ''U.S. Food and Drug Administration (FDA)''. 7 June 2011.</ref> </ins>Jepang, Uni Eropa, Kanada, dan Australia pada tahun 2011.<ins style="font-weight: bold; text-decoration: none;"><ref>[https://www.drugs.com/monograph/linagliptin.html Linagliptin Monograph for Professionals]. ''Drugs.com''. American Society of Health-System Pharmacists.</ref><ref>[https://pro.boehringer-ingelheim.com/products/trajenta/10years#pre2011 10 years]. ''Boehringer Ingelheim Limited''.</ref></ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Penamaan==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Penamaan==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Linagliptin adalah [[Nama Generik Internasional]] (INN). Nama merek: Trajenta, dll.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Linagliptin adalah [[Nama Generik Internasional]] (INN).<ins style="font-weight: bold; text-decoration: none;"><ref>[https://www.who.int/medicines/publications/druginformation/innlists/RL61.pdf International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names: List 61]. World Health Organization. hlm. 66.</ref> </ins>Nama merek: Trajenta,<ins style="font-weight: bold; text-decoration: none;"><ref>[https://www.nhs.uk/medicines/linagliptin/ Linagliptin: medicine to treat type 2 diabetes]. ''NHS UK''. 25 March 2022.</ref> </ins>dll.</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Kegunaan dalam medis==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Kegunaan dalam medis==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Linagliptin diindikasikan sebagai tambahan diet dan olahraga untuk meningkatkan kontrol glikemik pada orang dewasa dengan diabetes melitus tipe 2.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Linagliptin diindikasikan sebagai tambahan diet dan olahraga untuk meningkatkan kontrol glikemik pada orang dewasa dengan diabetes melitus tipe 2.<ins style="font-weight: bold; text-decoration: none;"><ref>[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c797ea5c-cab7-494b-9044-27eba0cfe40f Tradjenta- linagliptin tablet, film coated]. ''DailyMed''. 21 April 2022.</ref></ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Efek samping==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Efek samping==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Linagliptin dapat menyebabkan nyeri sendi yang parah.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Linagliptin dapat menyebabkan nyeri sendi yang parah.<ins style="font-weight: bold; text-decoration: none;"><ref>[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid</ins>=<ins style="font-weight: bold; text-decoration: none;">c797ea5c-cab7-494b-9044-27eba0cfe40f Tradjenta- linagliptin tablet, film coated]. ''DailyMed''. 21 April 2022.</ref><ref>[https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain]. ''U.S. Food and Drug Administration (FDA)''. 28 August 2015.</ref></ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td colspan="2" class="diff-side-added"></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">==Referensi=</del>=</div></td><td colspan="2" class="diff-side-added"></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Pranala luar==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Pranala luar==</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">== Referensi ==</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><references /></ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">== Sumber dan atribusi ==</ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>== <del style="font-weight: bold; text-decoration: none;">Sumber </del>dan <del style="font-weight: bold; text-decoration: none;">atribusi ==</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Konten artikel ini diadaptasi dari [https://id.wikipedia.org/w/index.php?title</ins>=<ins style="font-weight: bold; text-decoration: none;">Linagliptin&oldid</ins>=<ins style="font-weight: bold; text-decoration: none;">29568434 Wikipedia bahasa Indonesia], revisi 29568434 (2026-08-12T23:20:29Z), yang tersedia berdasarkan lisensi Creative Commons Atribusi-BerbagiSerupa (CC BY-SA). Gambar pada artikel ini bersumber dari Wikimedia Commons </ins>dan <ins style="font-weight: bold; text-decoration: none;">mengikuti ketentuan lisensi masing-masing berkas. Mohon gunakan konten dan media secara bijak serta sesuai dengan ketentuan lisensi yang berlaku.</ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Konten artikel ini diadaptasi dari [https://id.wikipedia.org/w/index.php?title=Linagliptin&oldid=29568434 Wikipedia bahasa Indonesia], revisi 29568434 (2026</del>-<del style="font-weight: bold; text-decoration: none;">08</del>-<del style="font-weight: bold; text-decoration: none;">12T23:20:29Z), yang tersedia berdasarkan lisensi Creative Commons Atribusi</del>-<del style="font-weight: bold; text-decoration: none;">BerbagiSerupa (CC BY</del>-<del style="font-weight: bold; text-decoration: none;">SA). Mohon gunakan konten ini secara bijak serta sesuai dengan ketentuan lisensi yang berlaku.</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><!</ins>-- <ins style="font-weight: bold; text-decoration: none;">WIKI_UNISSULA_PRESENTATION_V4 </ins>--<ins style="font-weight: bold; text-decoration: none;">></ins></div></td></tr>
</table>
Maintenance script
https://wiki.unissula.ac.id/index.php?title=Linagliptin&diff=27107&oldid=prev
Maintenance script: Impor teks terkontrol dari Wikipedia bahasa Indonesia; revisi 29568434; atribusi sumber disertakan.
2026-08-29T17:38:01Z
<p>Impor teks terkontrol dari Wikipedia bahasa Indonesia; revisi 29568434; atribusi sumber disertakan.</p>
<p><b>Halaman baru</b></p><div>'''Linagliptin''' adalah obat yang digunakan untuk mengobati [[diabetes melitus tipe 2]] bersamaan dengan olahraga dan diet. Linagliptin termasuk dalam kelas obat yang disebut "[[penghambat dipeptidil peptidase-4]]". Obat ini secara umum kurang disukai dibandingkan [[metformin]] dan [[sulfonilurea]] sebagai pengobatan awal. Obat ini digunakan dengan cara diminum.<br />
<br />
[[Efek samping]] yang umum termasuk radang hidung dan tenggorokan. Efek samping yang serius mungkin termasuk [[edema angioneurotik|angioedema]], [[pankreatitis]], nyeri sendi. Penggunaan pada [[kehamilan]] dan [[menyusui]] tidak dianjurkan. Linagliptin adalah penghambat dipeptidil peptidase-4 yang bekerja dengan meningkatkan produksi [[insulin]] dan menurunkan produksi [[glukagon]] oleh pankreas.<br />
<br />
Linagliptin telah disetujui untuk penggunaan medis di Amerika Serikat, Jepang, Uni Eropa, Kanada, dan Australia pada tahun 2011.<br />
<br />
==Penamaan==<br />
Linagliptin adalah [[Nama Generik Internasional]] (INN). Nama merek: Trajenta, dll.<br />
<br />
==Kegunaan dalam medis==<br />
Linagliptin diindikasikan sebagai tambahan diet dan olahraga untuk meningkatkan kontrol glikemik pada orang dewasa dengan diabetes melitus tipe 2.<br />
<br />
==Efek samping==<br />
Linagliptin dapat menyebabkan nyeri sendi yang parah.<br />
<br />
==Referensi==<br />
<br />
==Pranala luar==<br />
<br />
<br />
<br />
== Sumber dan atribusi ==<br />
<br />
Konten artikel ini diadaptasi dari [https://id.wikipedia.org/w/index.php?title=Linagliptin&oldid=29568434 Wikipedia bahasa Indonesia], revisi 29568434 (2026-08-12T23:20:29Z), yang tersedia berdasarkan lisensi Creative Commons Atribusi-BerbagiSerupa (CC BY-SA). Mohon gunakan konten ini secara bijak serta sesuai dengan ketentuan lisensi yang berlaku.</div>
Maintenance script